Details for Patent: 12,059,410

Which drugs does patent 12,059,410 protect, and when does it expire?

Patent 12,059,410 protects QINLOCK and is included in one NDA.

This patent has twenty-one patent family members in twelve countries.

Drugs Protected by US Patent 12,059,410

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Deciphera Pharms	QINLOCK	ripretinib	TABLET;ORAL	213973-001	May 15, 2020		RX	Yes	Yes	12,059,410					TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB

International Family Members for US Patent 12,059,410

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	122301
Australia	2020328538
Australia	2020329956
Australia	2023286024
Brazil	112022002609
Canada	3150433